Shouichi Higashi

Title: Shouichi Higashi: Innovator in Matrix Metalloproteinase Inhibition

Introduction

Shouichi Higashi is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of innovative therapeutic agents. With a total of 2 patents, his work focuses on inhibiting matrix metalloproteinases, which play a crucial role in various diseases.

Latest Patents

Higashi's latest patents include a fusion protein composed of a matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2. This invention provides an agent capable of specifically inhibiting MMP-2. The disclosed fusion molecule consists of a β-amyloid precursor protein-derived domain that selectively inhibits matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase that binds to latent matrix metalloproteinase. Additionally, he has developed a modified TIMP, which is a novel modified tissue inhibitor of metalloproteinase. This modification involves altering the NH-terminal α-amino group with an electron-accepting group, resulting in a substantial loss of the ability to bind to metalloproteinases.

Career Highlights

Shouichi Higashi is associated with Oriental Yeast Co., Ltd., where he continues to advance his research and innovations. His work has implications for cancer metastasis, angiogenesis inhibition, and therapeutic applications for cardiovascular diseases.

Collaborations

Higashi collaborates with Kaoru Miyazaki, contributing to the development of innovative solutions in their field.

Conclusion

Shouichi Higashi's contributions to matrix metalloproteinase inhibition highlight his role as a significant inventor in biochemistry. His innovative patents pave the way for potential therapeutic advancements in various medical conditions.